Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I)

European Journal of Echocardiography

Volumn 7, Issue 6, 2006, Pages 439-446

  Collins, Nicholas ^a   Bastian, Bruce ^a   Quiqueree, Laurent ^a   Jones, Carol ^b   Morgan, Renae ^b   Reeves, Glenn ^b  

^a JOHN HUNTER HOSPITAL   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

Author keywords

CREST; Pulmonary hypertension; Scleroderma; Stress echocardiography

Indexed keywords

ADULT; AGED; ARTICLE; AUTOIMMUNITY; DATA BASE; DISEASE SEVERITY; EXERCISE; FEMALE; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY ARTERY DISEASE; PULMONARY HYPERTENSION; REGISTER; SCREENING TEST; STRESS ECHOCARDIOGRAPHY; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TRICUSPID VALVE REGURGITATION;

AGED; AUTOIMMUNE DISEASES; CREST SYNDROME; ECHOCARDIOGRAPHY, STRESS; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY ARTERY;

EID: 33750031478     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1016/j.euje.2005.12.002     Document Type: Article

References (37)

1. Battle R.W., Davitt M.A., Cooper S.M., Buckley L.M., Leib E.S., Beglin P.A., et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 110 6 (1996) 1515-1519
2. Hachulla E., and Coghlan J.G. A new era in the management of pulmonary arterial hypertension related to scleroderma:endothelin receptor antagonism. Ann Rheum Dis 63 (2004) 1009-1014
3. MacGregor A.J., Canavan R., Knight C., Denton C.P., Dawar J., Coghlan J., et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 40 (2001) 453-459
4. Kuwat S.M., Taichman D.B., Archer-Chicko C.L., Palevsky H.I., and Kimmel S.E. Hemodynamic and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123 (2003) 344-350
5. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., et al. Effects of the dual endothelin antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
6. Ghofrani H.A., Pepke-Zaba J., Barbera J.A., Channick R.N., Keogh A.M., Gomez-Sanchez M.A., et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary hypertension. J Am Coll Cardiol 43 12 (2004) 68S-72S
7. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for pulmonary hypertension. N Engl J Med 334 (1996) 296-302
8. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Nerve P., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
9. Badesch D.B., McLaughlin V.V., Delcroix M., Vizza C.D., Olschewski H., Sitbon O., et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43 12 (2004) 56S-61S
10. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary artery hypertension. N Engl J Med 346 (2002) 896-903
11. Liu C., and Cheng J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 25 1 (2005) CD004434
12. McLaughlin V.V., Sitbon O., Badesch D.B., Barst R.J., Black C., Galie N., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 2 (2005) 244-249
13. Keogh A.M., McNeil K.D., Williams T., Gabbay E., and Cleland L.G. Pulmonary arterial hypertension: a new era in management. Med J Aust 178 (2003) 564-567
14. Magliano M., Isenberg D.A., and Hillson J. Pulmonary hypertension in autoimmune rheumatic diseases: where are we now?. Arthritis Rheum 46 8 (2002) 1997-2009
15. Recommendations on the management of pulmonary hypertension in clinical practice. British cardiac society guidelines and medical practice committee. Heart 86 Suppl. I (2001) i1-i13
16. Marwick T.H. Application of stress echocardiography to the evaluation of non-coronary heart disease. Eur J Echocardiogr 1 3 (2000) 171-179
17. Grunig E., Janssen B., Mereles D., Barth U., Borst M.M., Vogt I.R., et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 102 (2000) 1145-1150
18. Barbant S.D., Redberg R.F., Tucker K.J., Chatterjee K., DeMarco T., Foster E., et al. Abnormal pulmonary artery pressure profile after cardiac transplantation: an exercise Doppler echocardiographic study. Am Heart J 129 6 (1995) 1185-1192
19. McGoon M., Gutterman D., Steen V., Barst R., McCrory D.C., and Fortin T.A. Screening, early detection and diagnosis of pulmonary arterial hypertension. Chest 126 (2004) 14S-34S
20. Arcasoy S.M., Christie J.D., Ferrari V.A., Sutton M.S., Zisman D.A., Blumenthal N.P., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167 (2003) 735-740
21. Homma A., Anzueto A., Peters J.I., Susanto I., Sako E., Zabalgoitia M., et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterisation in patients awaiting lung transplantation. J Heart Lung Transplant 20 8 (2001) 833-839
22. Denton C.P., Cailes J.B., Phillips G.D., Wells A.U., Black C.M., and Bois R.M. Comparison of Doppler echocardiography and right heart catheterisation to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36 2 (1997) 239-243
23. Schachna L., Wigley F.M., Chang B., White B., Wise R.A., and Gelber A.C. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 124 (2003) 2098-2104
24. Personal communication. Actelion pharmaceuticals Pty. Ltd. Sydney, Australia.
25. Reeves G. An update on the immunology, diagnosis and management of lupus. J Intern Med 34 6 (2004) 338-347
26. Steen V., and Medsger T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48 2 (2003) 516-522
27. Krowka M.J. Hepatopulmonary syndrome and portopulmonary hypertension. Curr Treat Options Gastroenterol 4 (2001) 539-545
28. Capponnolla S., Febo O., and Guazzotti G. Invasive and noninvasive determinants of pulmonary hypertension in patients with chronic heart failure. J Heart Lung Transplant 19 (2000) 426-438
29. Preston I.R., and Hill N.S. Evaluation and management of pulmonary hypertension in systemic sclerosis. Curr Opin Rheumatol 15 (2003) 761-765
30. Murkejee D., St George D., Coleiro B., Knight C., Denton C.P., Davar J., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62 (2003) 1088-1093
31. McQuillan B.M., Picard M.H., Leavitt M., and Weyman A.E. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 104 (2001) 2797-2809
32. Borgeson D.D., Seward J.B., Miller F.A., Oh J.K., and Tajik A.J. Frequency of Doppler measurable pulmonary artery pressures. J Am Soc Echocardiogr 9 (1996) 832-837
33. Chemia D., Castelain V., Humbert M., Herbert J.C., Simonneau G., Lecarpentier Y., et al. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest 126 4 (2004) 1313-1317
34. Galie N., Hinderliter A.L., Torbicki A., Fourme T., Simonneau G., Pulido T., et al. J Am Coll Cardiol 41 (2003) 1380-1386
35. Galie N., Manes A., and Branzi A. Evaluation of pulmonary arterial hypertension. Curr Opin Cardiol 19 (2004) 575-581
36. Higenbottam T., Stenmark K., and Simonneau G. Treatments for severe pulmonary hypertension. Lancet 353 (1999) 338-339
37. Gaine S.P., and Rubin L.J. Primary pulmonary hypertension. Lancet 352 (1998) 719-725